
The ONS Podcast
- Format:
- Podcast
- New episodes:
- Weekly
- Typical length:
- about 35 minutes
- Latest episode:
About this show
Where ONS Voices Talk Cancer
Join oncology nurses on the Oncology Nursing Society's award-winning podcast as they sit down to discuss the topics important to nursing practice and treating patients with cancer.
ISSN 2998-2308
Covers: oncology nursing, cancer care, cancer treatment, patient education, precision oncology, oncologic emergencies, hematologic cancers, nursing leadership
Show details and episodes come from the publisher's public feed at rss.libsyn.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The ONS Podcast, from the Oncology Nursing Society, has oncology nurses discussing cancer care topics that matter to nursing practice and patients. Recent episodes cover biomarker testing, reframing care at end of life, inpatient rehabilitation during cancer treatment, Hodgkin lymphoma, and oncologic emergencies such as hypersensitivity reactions.
Cosmos
Similar by topic and creator
- The Crappy Childhood Fairy Podcast with Anna Runkle
Shares the topics Education and Health. - The Mel Robbins Podcast
Shares the topics Education and Health. - Feeling Things with Amy & Kat
Shares the topics Education and Health.
Similar shows
- The Organic Chemistry Tutor
- The Organized Coach - Productivity, Business Systems, Time Management, ADHD, Routines, Life Coach, Entrepreneur
- The Orvis Fly-Fishing Podcast
- The Other Side NDE (Near Death Experiences)
- The Overwhelmed Brain
- The Par Train | Get Off the Struggle Bus
- The Parrot Podcast
- The Paul Parent Garden Club
Explore more
Episodes
Episode 422: An Overview of Chronic Lymphocytic Leukemia for Oncology Nurses
· 47 min
"What I appreciate about our patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia is the consideration that they receive a cancer diagnosis, and the best thing for them to do is actually nothing. There is a large population of patients that we don't recommend any type of treatment. We recommend that they establish care with an oncologist and that they have a relationship with those care teams," ONS member Caitlin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about an overview of CLL for oncology nurses. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 3, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of the diagnosis and management of chronic lymphocytic leukemia. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer - Episode 256: Cancer Symptom Management Basics: Hematologic Complications - ONS Voice articles: - Compensation Funds Curb Financial Burden for Certain Exposure-Related Cancers - Infection Prevention for Oncology Nurses - Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment - Patient Stress Linked to More Advanced Leukemia - Patients With CLL Report Worse QoL and Other Factors - Clinical Journal of Oncology Nursing articles: - Care Coordination: Overcoming Barriers to Improve Outcomes for Patients With Hematologic Malignancies in Rural Settings - Pseudohyperkalemia in Chronic Lymphocytic Leukemia: An Often Overlooked Clinical Entity - Richter Transformation Arising From Chronic Lymphocytic Leukemia - ONS book: Site-Specific Cancer Series: Leukemia (first edition) - Hematology, Cellular Therapy and Stem Cell Transplantation Learning Library - ONS Biomarker Database (https://www.ons.org/clinical-tools/biomarkers) - ONS clinical practice resource: Genomics Taxonomy - Blood Cancer United: Chronic Lymphocytic Leukemia: In Detail - CLL Society: Patient Education Toolkit - Lymphoma Research Foundation: Lymphoma and CLL Publications - National Comprehensive Cancer Network (https://www.nccn.org/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the common risk factors are environmental exposures, occupational exposures, and chemical exposures. For example, in certain farming communities where there are pesticides, that can definitely contribute to the risk of developing CLL. There's some consideration for high levels of radon exposure or exposure to Agent Orange. So our veterans, both from the Vietnam War but also more recently in Iraq. There's definitely a consideration that those types of exposures increase the risk of developing CLL." TS 3:01 "Generally, the average age of diagnosis for CLL is in the seventh decade of life. But over 90% of people are diagnosed at age 50 and above. So, this tends to be a diagnosis in the six or seventh decade of life. It's extremely rare in children, although it has been observed, and…
Not rated yetEpisode 421: Medical Trauma in Oncology
· 41 min
"There are a huge array of medical dynamics that people endure, and when they leave a lasting impact, a word that we don't use widely enough is the word 'trauma.' There's an entire category of phenomena in the medical arena that are, in fact, traumatic. One way we know that these experiences are traumatic is that we know that huge portions of people who experience things like cancer do indeed develop problems like [post-traumatic stress disorder]," James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about understanding medical trauma in oncology. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 26, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of medical trauma and its effects on patients with cancer, caregivers, and healthcare professionals. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 315: Processing Grief as an Oncology Nurse - Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care - Episode 276: Support Young Families During a Parent's Cancer Journey - Episode 257: Redefining the Bell: The Ethics of Hope for Oncology Nurses and Patients - Episode 103: What Oncology Nurses Need to Know to Support Caregivers - ONS Voice articles: - 'Between Two Kingdoms' Gives Us a Glimpse Into How Patients and Families Experience Malignancy - AYA Cancer Survivors Experience Five Times Higher Depression Rates Than Individuals Diagnosed at Older Ages - From Stigma to Support: Changing the Cancer Conversation - Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD - Moral Injury and Trauma in Nursing - Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress - When the Story Ends, Cancer Does Not Win: Reframing Death in Terminal Cancer Care - Word Choice Matters When Caring for Patients With Cancer - ONS course: ONS Psychosocial Dimensions of Cancer Care™ - Clinical Journal of Oncology Nursing articles: - Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach (https://doi.org/10.1188/22.CJON.11-13) - Trauma-Informed Care Addressing the Mental and Emotional Needs of Patients With Cancer (https://doi.org/10.1188/24.CJON.372-379) - Oncology Nursing Forum articles: - Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers (https://doi.org/10.1188/23.ONF.35-46) - The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy (https://doi.org/10.1188/26.ONF.e26535307) - Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Many people have a notion about what medical trauma is, but perhaps they lack a definition. I use a definition that is deliberately broad because I think it is better to be inclusive than exclusive.…
Not rated yetEpisode 420: Long-Term Myelodysplastic Syndrome Considerations for Oncology Nurses
· 43 min
"We typically think of the disease progressing for our higher-risk patients because many of them already start with increased blasts or a lot of dysplasia. And they have these chromosomal variants that make them prone to evolving into acute myeloid leukemia (AML). With them, we can anticipate that they are going to progress to AML. And that's what we're trying to prevent. It's kind of like a biologic evolution and not a switch," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term myelodysplastic syndrome (MDS) considerations for oncology nurses. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 19, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to myelodysplastic syndrome and its treatment. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 415: Myelodysplastic Syndrome Treatment Considerations for Oncology Nurses - Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses - Episode 256: Cancer Symptom Management Basics: Hematologic Complications - Episode 220: Oncologic Emergencies 101: Febrile Neutropenia and Sepsis - Clinical Journal of Oncology Nursing articles: - Exploring Experiences of Bereaved Caregivers of Older Adult Patients With Acute Myeloid Leukemia - Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management - Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery - Oncology Nursing Forum article: An Integrative Review of Sex Differences in Quality of Life and Symptoms Among Survivors of Hematologic Malignancies - ONS book: BMTCN® Certification Review Manual (second edition) - ONS course: Psychosocial Dimensions of Cancer Care™ - ONS Learning Libraries: - Survivorship Learning Library - Hematology, Cellular Therapy, and Stem Cell Transplantation - Survivorship Care Plan Huddle Card - American Association of Colleges of Nursing End-of-Life Nursing Education Consortium (ELNEC) (https://www.aacnnursing.org/elnec) - American Cancer Society: Living As a Myelodysplastic Syndrome Survivor - American Society of Hematology (https://www.hematology.org/) - Aplastic Anemia and MDS International Foundation: MDS Toolkit (https://www.aamds.org/mds/toolkit) - Blood Cancer United: Myelodysplastic Syndromes - Family Caregiver Alliance (https://www.caregiver.org) - HealthTree Foundation (https://healthtree.org/) - Inspire: MDS Support and Discussion Community - Myelodysplastic Syndromes Foundation (https://www.mds-foundation.org/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "When our higher-risk patients have disease-related progression, their [malignancy] can transform to AML. And we know this occurs in about one-third of our patients and is one of the most serious late effects. Even in lower-risk disease, we have this worsening marrow failure with or without increasing…
Not rated yetEpisode 419: Pharmacology 101: Immunomodulators
· 44 min
"Until immunomodulators, patients [with myeloma] did not have a great overall survival rate. But when we introduced lenalidomide, we started seeing our patients have life expectancies between five and seven years—which was unheard of prior to these immunomodulators going forward. I think it's promising and allows patients to have quality of life versus therapy of life," ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about immunomodulators. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 12, 2027. Daniel Verina is on the speakers' bureau for Johnson & Johnson, GlaxoSmithKline, and Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of immunomodulators to treat cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Pharmacology 101 series - Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses - Episode 386: Interprofessional Navigation and the Oral Anticancer Medication Care Compass - Episode 290: Cancer Symptom Management Basics: Peripheral Neuropathy - ONS Voice articles: - Maintain Oral Adherence With ONS Guidelines™ - Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations - Sexual Considerations for Patients With Cancer - Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles - Oncology Nursing Forum articles: - Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study - Facilitators of Multiple Myeloma Treatment: A Qualitative Study - ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) - ONS Symptom Intervention resource: Peripheral Neuropathy - Risk Evaluation and Mitigation Strategies (REMS) - Lenalidomide - Pomalidomide - Thalidomide (https://www.thalomidrems.com/) - International Myeloma Foundation: Using Immune Therapy to Fight Multiple Myeloma - International Myeloma Society (https://www.myelomasociety.org/) - Multiple Myeloma Research Foundation: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We definitely want the diagnosis of multiple myeloma before initiating these drugs. We're going to look at serum protein electrophoresis. We want to make sure that we know the patient has serum free light chains and myeloma proteins to really confirm their disease. Plus, a bone marrow biopsy." TS 7:21 "Each immunomodulator has slightly different side effects. Thalidomide's biggest side effects are constipation, weakness, fatigue, somnolence, peripheral neuropathy, mood swings, hand tremors, and depression. With each generation, less of the side effects actually occurred. Most of lenalidomide's side effects, not discounting the deep vein thrombosis, are pancytopenia—the neutropenia, the anemia, and the thrombocytopenia. [The side effects] are very similar in pomalidomide." TS 15:40 "The REMS program is critical for oral immunomodulator therapies—thalidomide,…
Not rated yetEpisode 418: Radiation Site-Specific Side Effects: Colorectal Cancer
· 28 min
"Radiation therapy is often extremely well tolerated in colorectal cancer. Technology has really changed things. But location of the tumor can affect side effects, such as radiation dermatitis. If a patient has a low-lying tumor, if it's less than six centimeters from the anal verge, the patient is likely to have some skin reaction. It's good to be proactive if that's the case," ONS member Lorraine Drapek, DNP, FNP-BC, AOCNP®, nurse practitioner in the Department of Radiation Oncology at Massachusetts General Hospital in Boston, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation side effects in colorectal cancer. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 5, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat colorectal cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 374: Colorectal Cancer Treatment Considerations for Nurses - Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices - Episode 194: Sex Is a Component of Patient-Centered Care - ONS Voice articles: - Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer - High-Fiber Diet Reduces Diarrhea in Colorectal Cancer Survivors - Hyperbaric Oxygen Therapy Shows Promise for Certain Radiation Side Effects - Increasing Incidence of Colorectal Cancer in Younger Adults Is a Call to Action for Oncology Nurses - Oncology Drug Reference Sheet: 5-Fluorouracil - Oncology Drug Reference Sheet: Oxaliplatin - Oncology Nurses Are Key in Sexual Health Conversations With Minority Women - Sexual Considerations for Patients With Cancer - The Intersection of Pelvic Health and Oncology Optimizes Sexual Symptom Management - ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) - ONS courses: - ONS/ONCC® Radiation Therapy Certificate™ - ONS ROCN™ Certification Review™ - Clinical Journal of Oncology Nursing articles: - Sexual Dysfunction: Common Side Effect (https://doi.org/10.1188/21.CJON.S2.16-20) - Updated Interventions for Radiation-Induced Diarrhea: Putting Evidence Into Practice With the Oncology Nursing Society (https://doi.org/10.1188/25.CJON.48-59) - Physical Activity: A Systematic Review to Inform Nurse Recommendations During Treatment for Colorectal Cancer (https://doi.org/10.1188/21.CJON.697-705) - ONS Learning Libraries: - Colorectal Cancer - Radiation - Advanced Practitioner Society for Hematology and Oncology (https://www.apsho.org/) - American Society for Radiation Oncology (https://www.astro.org/) - American Society of Clinical Oncology Clinical Practice Guidelines (https://ascopubs.org/guidelines) - Colontown (https://colontown.org/) - Colorectal Cancer Alliance (https://colorectalcancer.org/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In recent years, there has been more nonsurgical management of rectal cancer, especially in what we call the low-lying population. This is the population of patients who would likely…
Not rated yetEpisode 417: Pharmacology 101: Oncolytic Viral Therapy
· 35 min
"There are a lot of specifics that nurses need to keep in mind as they are administering this herpes simplex modified virus to patients because accidental exposure is of concern both to the patient, to their family members, as well as to healthcare workers. I always recommend nurses wear personal protective equipment, such as a gown, safety glasses, gloves, and/or a face shield," Heidi Finnes, PharmD, RPh, BCOP, director of clinical ambulatory practice at Mayo Clinic and assistant professor of pharmacy at Mayo Clinic Alix School of Medicine in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about oncolytic viral therapy. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 29, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of oncolytic viruses to treat cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Pharmacology 101 series - Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role - Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs - Episode 273: Updates in Chemotherapy and Immunotherapy - ONS Voice articles: - Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy - Oncolytic Virus Kills Tumor Cells While Supporting T Cells - What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma - Clinical Journal of Oncology Nursing articles: - Intralesional Therapy: Consensus Statements for Best Practices in Administration From the Melanoma Nursing Initiative - Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting - Oncology Nursing Forum article: Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma - ONS book: Guide to Cancer Immunotherapy (second edition) - ONS clinical practice resource: Safe Handling of Oncolytic Viruses - ONS Huddle Card: Immunotherapy - Association of Community Cancer Centers (ACCC) (https://www.accc-cancer.org/) - Drugs@FDA - Hematology/Oncology Pharmacy Association (HOPA) (https://www.hoparx.org/) - Network for Collaborative Oncology Development and Advancement (NCODA) (https://ncoda.org/) - Patient Education Sheets (https://patienteducationsheets.com/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "[Oncolytic viruses] can have direct lysis to the tumor cells themselves, or they can cause immunogenic activation. They release tumor-associated antigens and then proinflammatory signals, so think of T cells, natural killer cells, those sorts of things, that can convert to immunologically cold tumors. Those are tumors that are immune silenced into hot tumors which are now immune activated. By doing that, they recruit those T cells and other cells to the area to attack both the primary tumors. But that's also thought to be how they work on distant or noninjected sites as well. This immunomodulatory capacity has led to the reclassification of oncolytic viruses as a form of…
Not rated yetEpisode 416: Cancer Treatments for Noncancer Indications: Radiation
· 21 min
"When you have benign conditions, we're actually treating 3 gray, so a significant difference [versus doses of 60 gray for brain cancer]. Typically, when you treat at a high dose, the goal is to destroy tissue, like cancer tissue or cancer cells. But when we give a low dose, the goal is actually to modulate inflammation. And what it does is it slows down those inflammatory cells or those cells that release the chemicals that cause pain and inflammation," Amanda Meyer, DNP, APRN, CNP, family nurse practitioner in the Department of Radiation Oncology at the Mayo Clinic in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation therapy for noncancer indications. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 22, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of radiation to treat noncancerous conditions. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 365: Radiation-Associated Secondary Cancers - Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices - ONS Voice articles: - Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy - Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education - Quick Quiz: Test Your Knowledge of Radiation Care Coordination - ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) - ONS courses: - ONS Radiation Oncology Conference Recordings Bundle™ - ONS ROCN™ Certification Review™ - Radiation Oncology 101: 2024 ONS Bridge™ Session - ONS/ONCC® Radiation Therapy Certificate™ - Clinical Journal of Oncology Nursing articles: - Findings From the 2023 Radiation Oncology Nursing Role Delineation Study to Shape the Future of the Subspecialty (https://doi.org/10.1188/24.CJON.598-603) - The Role of Advanced Practice Providers in Radiation Oncology in 2025 (https://doi.org/10.1188/25.CJON.279-284) - ONS Huddle Cards: - Radiation - Radiobiology - German Society for Radiation Oncology (DEGRO): Guidelines in Radiotherapy: Radiotherapy for Benign Diseases To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We always typically think of it as cancer treatment, but we can use radiation for noncancerous conditions, as well. And radiation was actually used for benign diseases right after the discovery of x-rays. By the 1920s it was used a lot for different types of musculoskeletal, dermatologic issues, and different types of inflammatory conditions. And over time, since the 1920s, we've actually really gotten a really good understanding of it." TS 1:37 "When we're looking at what are good candidate characteristics, we do typically like older patients, so patients over the age of 65. And the rationale behind that is we know that there is a potential for a secondary risk of a skin cancer about 20 to 30 years after getting low-dose radiation, like a basal cell or squamous cell skin cancer. The older the patient is, the less likely they are to have…
Not rated yetEpisode 415: Myelodysplastic Syndrome Treatment Considerations for Oncology Nurses
· 30 min
"We want to make sure that we discuss the details of the treatment and what treatments there are, whether it's an oral drug, whether it's a subcutaneous injection or an IV injection, [the patient's] potential for responding, whether this treatment is curative or supportive, and what the number of visits are. All of those different pieces of information that go into the decision-making process are really important," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about myelodysplastic syndrome (MDS) treatment considerations. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 15, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the treatment considerations for MDS. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses - Episode 256: Cancer Symptom Management Basics: Hematologic Complications - ONS Voice articles: - FDA Approves Luspatercept-Aamt for Anemia in Adults With MDS - Infection Prevention for Oncology Nurses - Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents - Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS - Clinical Journal of Oncology Nursing articles: - Reducing Effects of Hospital-Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Resilience in Older Adults Diagnosed With Cancer and Receiving Chemotherapy - Targeted Drug Therapies: Beyond Blood Counts and Chemistries - Oncology Nursing Forum article: Frailty in Patients With Hematologic Malignancies and Those Undergoing Transplantation: A Scoping Review - ONS books: - BMTCN™ Certification Review Manual (second edition) - Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) - ONS course: Hematopoietic Stem Cell Transplantation™ - ONS Learning Library: Hematology, Cellular Therapy, and Stem Cell Transplantation - ONS Symptom Intervention resources: - Prevention of Infection: General - Prevention of Infection: Transplant - Aplastic Anemia and MDS International Foundation: MDS Drugs and Treatments (https://www.aamds.org/mds/drugs-treatments) - Blood Cancer United: MDS Treatment - HealthTree Foundation (https://healthtree.org/) - Myelodysplastic Syndromes Foundation (https://www.mds-foundation.org/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The goals that I try to consolidate to make sure they're consistent with the patient's goals are to improve their counts, especially the anemia or cytopenias. If they're getting blood transfusions, we want to reduce the number of transfusions that they receive because we know that's linked to reduced overall survival, and it really impacts quality of life. ... And then for high-risk patients, it's a more serious discussion because we know that they are the ones who can progress to acute myeloid leukemia (AML). And we're trying…
Not rated yetEpisode 414: Radiation Site-Specific Side Effects: Lung Cancer
· 14 min
"Skin reactions, such as redness, dryness, and just irritation of the skin, can occur. Since we're irradiating the lung, we can also cause a cough, and that's due to the inflammation from the radiation. Patients can also get esophagitis if the tumor that we're treating is close to the midline of the chest near the esophagus. And probably the most common side effect that we see is fatigue," ONS member Amy MacRostie, RN, OCN®, radiation oncology nurse at St. Charles Cancer Center in Bend, OR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation side effects in lung cancer. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 8, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat lung cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 369: Lung Cancer Survivorship Considerations for Nurses - Episode 363: Lung Cancer Treatment Considerations for Nurses - Episode 359: Lung Cancer Screening, Early Detection, and Disparities - Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications - Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion - ONS Voice article: Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education - ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) - ONS courses: - ONS/ONCC® Radiation Therapy Certificate™ - ONS ROCN™ Certification Review™ - ONS Radiation Learning Library - ONS Guidelines™ and Symptom Intervention Resources - National Comprehensive Cancer Network (https://nccn.org/) - LUNGevity Foundation (https://www.lungevity.org/) - Inspire Lung Cancer Survivors Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The types of radiation that can be used are external beam radiation and stereotactic body radiation treatment, or SBRT. External beam radiation is often used in combination with other treatment modalities, like chemotherapy, immunotherapy, and targeted therapy, to treat these cancers. And SBRT is usually done solo, and it's a highly precise treatment for inoperable or early-stage lung cancers." TS 1:52 "[Physicians and] providers can also help prevent side effects by reducing the dose to the heart and reducing the dose to the good lung tissue, if you will, as much as they possibly can. And this is done using intensity-modulated techniques, or IMRT. And that's where the linear accelerator sculpts the radiation beams conforming to the shape of the tumor itself." TS 6:37 "I think overall cancer treatment can lead to decreased libido and decreased sexual interest. Depression and fear can definitely play a role in this. And with lung radiation, specifically, fatigue and possibly shortness of breath with the exertion may decrease sexual interest. Nurses and providers should support the patient in their desire or lack thereof in sexual activities. We should have open discussions … and these can take place…
Not rated yetEpisode 413: Intrarenal Administration for Upper Urothelial Tract Disease: The Oncology Nurse's Role
· 41 min
"We thought, from a nursing standpoint, 'What is our goal for doing this?' What we wanted was first, education of the patient. Can we successfully educate the patient to prepare them? Can we alleviate as much anxiety as possible so that they feel comfortable coming in and having this done? The second goal is to preserve kidney function throughout the treatment. To date, we've been successful with that. And the third goal is to complete treatment without infection," ONS member Chris Amoroso, BSN, RN, OCN®, registered nurse at Fox Chase Cancer Center in Philadelphia, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about intrarenal administration for upper urothelial tract disease. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 1, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge of the different routes for drug administration, including intrarenal administration via a percutaneous nephrostomy. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 141: Care Coordination for Urothelial Cancer - Episode 133: Treatment Advancements for Advanced or Metastatic Urothelial Cancer - ONS Voice articles: - A Primer on Urothelial Cancer - Chemo Combo May Be a Bladder Cancer Treatment Alternative During BCG Shortage - Nurses Are Key to Patients Navigating Genitourinary Cancers - Clinical Journal of Oncology Nursing articles: - Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma - Percutaneous Nephrostomy Infusion: Nursing Considerations for Treatment of Upper Urinary Tract Urothelial Carcinoma - ONS Learning Libraries: - Cancer of the Genitourinary Tract - Safe Handling of Hazardous Drugs To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In an office setting, it's not something we can really visualize. Patients will present with hematuria or flank pain, obstructions in the ureter, some hydronephrosis, they may be having a lot of urinary tract infections. And a routine cystoscopy in the office is not going to visualize the ureters. We can do biopsies like a ureteroscopy, a computerized tomography urogram, or a urine cytology. And those are usually the main ways of diagnosing upper tract disease—again, because it's rare." TS 2:33 "We ask patients to get into a comfortable position where they can sit or lay for an hour without too much movement. The movement of their body position can interfere with the flow of the medication going in. ... When we're ready to start, we're cleaning the ends of the nephrostomy tube and the IV tubing with a chlorhexidine solution. We're instilling this using micro drip tubing. The tubing has to be microchipped so we can accurately control the flow. The IV bag with medication is hung about 10 inches above kidney level. And the reason we do that is because we do not want to increase the intrarenal pressure. ... We want a slow infusion via gravity over about an hour. We're watching throughout the procedure to make sure that there's no leakage, no discomfort, really just watching the…
Not rated yetEpisode 412: Pharmacology 101: Cytokines
· 35 min
"They are small, powerful little nuggets. They are actually small signaling proteins that our immune cells use to communicate. They really help regulate immune activation or inflammation and even the growth and survival of immune cells. When cytokines are used therapeutically in oncology, they help to stimulate immune cells such as T cells or natural killer cells to better recognize and attack cancer cells," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center of Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the cytokine drug class. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours (including 30 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 24, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge of cytokines to provide appropriate education and to safely administer related therapies. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Pharmacology 101 series - Episode 256: Cancer Symptom Management Basics: Hematologic Complications - Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis - ONS Voice articles: - FDA Approves Nogapendekin Alfa Inbakicept-Pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer - Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents - Oncology Drug Reference Sheet: Motixafortide - ONS books: - Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) and 2024 Drug Supplement - Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) - Guide to Cancer Immunotherapy (second edition) - Clinical Journal of Oncology Nursing article: - Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Nursing Considerations (https://doi.org/10.1188/25.CJON.125-129) - What's Old Is New Again, Unfortunately (https://doi.org/10.1188/26.CJON.92-93) - ONS Symptom Interventions - Colony-Stimulating Factors Including Biosimilars for At-Risk Patients for Prevention of Infection: General - Platelet Growth Factors for Prevention of Bleeding - National Comprehensive Cancer Network (http://www.nccn.org/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Cytokines are actually among some of the earliest forms of immunotherapy used in the treatment of cancer, and it really goes back to the 1980s and the 1990s. We're talking therapies like interferon [alpha] or interleukin-2 that were used to stimulate the immune system, with the idea that they would recognize and attack cancer cells, particularly in diseases like metastatic melanoma and renal cell carcinoma. What made these therapies unique was that although the overall response rates were relatively modest, when patients did respond, those responses could be very durable and sometimes long lasting. And that observation was really important for the field of oncology, because it was part of the process that demonstrated that the immune system could potentially control cancer in really meaningful ways." TS 1:49 "One nice new example of an…
Not rated yetEpisode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses
· 34 min
"Not every patient with myelodysplastic syndrome (MDS) is going to progress and die. Only 10%–20% of them will evolve into acute myeloid leukemia. And not all of them need blood transfusions. Some present with low platelet count. It's not just people who are anemic that have MDS—it's different depending on what type of MDS they have. These are averages. We're giving you statistics based on averages, and you're an individual, so we want to treat you as an individual," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about myelodysplastic syndrome. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 17, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with myelodysplastic syndrome require knowledge of its pathophysiology, the presenting symptoms, and its diagnosis. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer - Episode 302: Patient Navigation Eliminates Disparities in Cancer Care - Episode 256: Cancer Symptom Management Basics: Hematologic Complications - ONS Voice articles: - Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents - Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS - Clinical Journal of Oncology Nursing articles: - Deciphering TP53 Mosaic Variants on Germline Biomarker Testing: Implications for Oncology Nurses - Myeloid Malignancies: Recognizing the Risk of Germline Predisposition and Supporting Patients and Families - Oncology Nursing Forum article: Impact of a Hematologic Malignancy Diagnosis and Treatment on Patients and Their Family Caregivers - ONS book: BMTCN™ Certification Review Manual (second edition) - ONS Clinical Practice resource: Genomics Taxonomy - Genomics and Precision Oncology Learning Library - American Cancer Society: Myelodysplastic Syndrome Prognostic Scores - Aplastic Anemia and MDS International Foundation (https://www.aamds.org/) - Blood Cancer United: MDS Diagnosis - HealthTree Foundation (https://healthtree.org/education) - Myelodysplastic Syndromes Foundation: What Is MDS? To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In the bone marrow maturation process, you have a pluripotent stem cell. You have myeloid and lymphoid, and then on the myeloid side, you make your white blood cells, your red blood cells, and your platelets. And during that maturation process, there's this problem that arises. It's called a clonal variation. Or something goes wrong as the cells go through that process year after year. It's called ineffective hematopoiesis. ... That process of becoming mature, functioning cells, arising from that hematopoietic stem cell is broken, and this leads to low blood counts. Usually, it's anemia, so the hemoglobin is low. You can see that the mean corpuscular volume (MCV) is really high, and those are clues that a patient might have MDS—anemia with a high MCV." TS 3:05 "The…
Not rated yetEpisode 410: The Evidence for the Environment's Impact on Cancer Outcomes
· 42 min
"Cancer and environmental disasters in particular, but the worsening of our environment, are really things that are great equalizers. And we recognize that we're all kind of in this world together. We can really face these issues on a more human level. I think always recognizing that if we look at something, we think, 'Well, that doesn't relate to me or that problem is it really isn't my problem'—it sure is," ONS member Margaret "Peggy" Rosenzweig, PhD, CRNP-C, AOCNP®, FAAN, ONS scholar-in-residence and distinguished service professor of nursing and Nancy Glunt Hoffman Chair in Oncology Nursing at the University of Pittsburgh School of Nursing in Pennsylvania told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the effects of the environment on cancer care and outcomes. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 10, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge to recognize and address how environmental factors influence cancer care delivery, patient outcomes, and workforce resilience. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 190: The Environment, Cancer, and Nurses' Role in Advocating for Climate Change - Episode 107: Social Determinants Lead to Unequal Access to Health Care - ONS Voice articles: - Most Oncology Nurses Want to Address Climate Change but Don't Know How to Start - Here's How the Environment Affects Cancer Care—and What Oncology Nurses Can Do About It - Climate Change Is Contributing to the Cancer Burden, and Nurses Must Take Action - Clinical Journal of Oncology Nursing articles: - Oncology Nurses' Awareness, Concern, Motivations, and Behaviors Related to Climate Change and Health (https://doi.org/10.1188/25.CJON.474-483) - Environmental Risk Factors: The Role of Oncology Nurses in Assessing and Reducing the Risk for Exposure (https://doi.org/10.1188/20.CJON.S2.31-38) - Oncology Nursing Forum articles: - Research Priorities of the Oncology Nursing Society: 2024–2027 (https://doi.org/10.1188/24.ONF.502-515) - The Impact of Climate Change Across the Cancer Control Continuum: Key Considerations for Oncology Nurses (https://doi.org/10.1188/25.ONF.6-14) (ONS white paper) - ONS Huddle Card: Environmental Health and Climate Change - ONS Congress® session: The Impact of Climate Change on Patient Care - Supportive Care in Cancer article: Climate Disasters and Oncology Care: A Systematic Review of Effects on Patients, Healthcare Professionals, and Health Systems - What If We Get It Right? (https://www.getitright.earth/) by Ayana Elizabeth Johnson - The Cancer–Climate Connection: Environmental Drivers of Cancer in the Climate Era (https://www.youtube.com/watch?v=5E0AC2QEz60) (webinar by AnnMarie L. Walton) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The process of establishing these research priorities usually happens every three or so years. And there's a lot of preliminary work of talking to multiple parties of interest regarding what they believe the research priorities are, what nurses are seeing…
Not rated yetEpisode 409: An Overview of Interventional Oncology for Nurses
· 29 min
"Interventional oncology has really evolved into an important component of modern cancer care and is often described now as the fourth pillar alongside medical, surgical, and radiation oncology. The specialty now encompasses a broad spectrum of image-guided procedures that support from cancer diagnosis, treatment, to effectively managing symptoms that are caused by the disease. In other words, what we're seeing is that across the continuum of care, IO is playing a vital role," ONS member Evelyn P. Wempe, DNP, MBA, APRN, ACNP-BC, AOCNP®, CRN, NEA-BC, executive director for advanced practice providers for the oncology service line at the University of Miami Sylvester Comprehensive Cancer Center in Florida, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about interventional oncology. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 3, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to interventional oncology as a treatment modality for cancer. Episode Notes - Complete this evaluation for free NCPD (https://loginlr.ons.org/sso/jwt/redirect/token?apikey=c27fb796-f5bd-43e6-91aa-59f080be0a44&jwtapp=lpuserservice&ui_locales=ons&return_url=https://login-services.ons.org/api/HttpTriggerLPuserServiceRedirect?alias=PE409). - ONS Podcast™ episodes: - Episode 347: Care Considerations for Radiopharmaceuticals and Theranostics in Patients With Cancer (https://www.ons.org/education-hub/oncology-nursing-podcast/episode-347-care-considerations-radiopharmaceuticals-and) - Episode 285: Transarterial Chemoembolization: The Oncology Nurse's Role (https://www.ons.org/education-hub/oncology-nursing-podcast/episode-285-transarterial-chemoembolization-oncology-nurses) - ONS Voice articles: - Advancements in Interventional Oncology Ease Pain and Limit Opioid Use (https://www.ons.org/publications-research/voice/news-views/02-2026/advancements-interventional-oncology-ease-pain-and) - Build Your Confidence in Understanding Vascular IO Procedures (https://www.ons.org/publications-research/voice/news-views/02-2026/build-your-confidence-understanding-vascular-io) - From Heat to Cold to Electrical Pulses, Here's How Percutaneous IO Can Preserve Life and Function (https://www.ons.org/publications-research/voice/news-views/02-2026/heat-cold-electrical-pulses-heres-how-percutaneous) - Interventional Oncology Is an Evolving Subspecialty for Oncology Nurses (https://www.ons.org/publications-research/voice/news-views/02-2026/interventional-oncology-evolving-subspecialty) - Clinical Journal of Oncology Nursing articles: - Interventional Oncology (December 2025 supplement) - Expanding the Scope: The Emergence of Interventional Oncology Nursing (https://doi.org/10.1188/25.CJON.S1.E1-E2) - The Evolution of Interventional Oncology and the Specialized Role of Oncology Nursing (https://doi.org/10.1188/25.CJON.S1.E20-E27) - Interventional Oncology Learning Library (https://www.ons.org/interventional-oncology-learning-library) - Interventional Oncology Huddle Card (https://www.ons.org/clinical-tools/huddle-cards/interventional-oncology-huddle-card) - Society of Interventional Oncology (https://www.sio-central.org/) - Association for Radiologic and Imaging Nursing (https://www.arinursing.org/) - Society of Interventional Radiology: Cancer resources (https://www.sirweb.org/for-patients/conditions-and-treatments/cancer/) -…
Not rated yetEpisode 408: Radiation Site-Specific Side Effects: Breast Cancer
· 34 min
"A side effect patients might experience is lymphedema. This is an increased buildup of lymphatic fluid in the tissues, either in the breast or in the arm and hand of the affected side. It's quite problematic for women. They might feel self-conscious. It might feel uncomfortable that the arm feels like it's throbbing or heavy. Clothing may not fit quite right. So we're always on the lookout for lymphedema," Maria Fenton-Kerimian, APRN, AOCNP®, nurse practitioner at Weill Cornell Medicine in New York, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation site-specific side effects in breast cancer. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 27, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to side effects experienced with radiation therapy to the breast. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer - Episode 354: Breast Cancer Survivorship Considerations for Nurses - Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices - Episode 298: Radiation Oncology: Nursing's Essential Roles - Episode 194: Sex Is a Component of Patient-Centered Care - ONS Voice articles: - Could High-Dose Radiation Be the Missing Link in Breast Cancer Immunotherapy? - Exercise Program Improves Quality of Life in Patients With Breast Cancer—and Keeps Them Moving Daily - Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer - How to Handle Even the Worst Radiation Therapy Side Effects - Clinical Journal of Oncology Nursing articles: - Instruments to Evaluate Self-Management of Radiation Dermatitis in Patients With Breast Cancer - The Effects of a Clinical Care Model on Quality Process Outcomes in Radiation Oncology - Oncology Nursing Forum articles: - Feasibility of Breast Radiation Therapy Video Education Combined With Standard Radiation Therapy Education for Patients With Breast Cancer - ONS Guidelines™ for Cancer Treatment–Related Radiodermatitis - ONS books: - Guide to Breast Care for Oncology Nurses - Manual for Radiation Oncology Nursing Practice and Education (fifth edition) - ONS/ONCC® courses: - Radiation Oncology Conference Recordings Bundle™ - Radiation Therapy Certificate™ - ONS Huddle Cards: - Altered Body Image - Late Effects of Cancer Treatment - Radiation - Sexuality - ONS Guidelines™: - Cancer Treatment–Related Lymphedema - Cancer Treatment–Related Radiodermatitis - ONS Learning Libraries: - Breast Cancer - Radiation - American Society for Radiation Oncology (ASTRO) (https://www.astro.org/) - National Comprehensive Cancer Network home page (https://www.nccn.org/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The goals of radiation to the breast are typically broken out into three different rationales. Either adjuvant treatment, where the tumor is removed surgically from the breast first and then radiation is delivered to lower the likelihood of return of the cancer. And…
Not rated yetEpisode 407: Pharmacology 101: CAR T-Cell Immunotherapy
· 48 min
"You want to try to act quickly and be able to know what the pathways are for appropriate escalating when a patient is having symptoms that are reflective of cytokine release syndrome (CRS) or neurotoxicity. These toxicities are very manageable and treatable when recognized early. To summarize, choosing the right patient, knowing the toxicity profile for each product, and acting early is really what helps to prevent severe outcomes with chimeric antigen receptor (CAR) T-cell therapy," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about CAR T-cell immunotherapy. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CAR T-Cell immunotherapy in the treatment of cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Pharmacology 101 series - Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies - Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation - Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome - ONS Voice articles: - A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities - CAR T-Cell Therapy Programs - Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy - Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes - ONS Voice oncology drug reference sheet: Lisocabtagene Maraleucel - Clinical Journal of Oncology Nursing articles: - CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma - CAR T-Cell Therapy: Updates in Nursing Management - Nursing Considerations in Navigating Patients Receiving CAR T-Cell Therapy - ONS book: Guide to Cancer Immunotherapy (second edition) - ONS Huddle Cards: - Chimeric Antigen Receptor T-Cell Therapy - Cytokine Release Syndrome - Immune Effector Cell–Associated Neurotoxicity Syndrome - Immunotherapy - Immuno-Oncology Learning Library - American Society of Gene and Cell Therapy: Learning Center - American Society for Transplantation and Cellular Therapy: Learning Center (https://learn.astct.org/) - National Comprehensive Cancer Network home page (https://www.nccn.org/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "CAR T-cell therapy combines an adoptive cell transfer with genetic engineering. And what that really means is that we are harvesting a patient's own T cells and then we engineer them with a synthetic receptor that helps them recognize that cancer. And all of this work has evolved through many decades of stepwise advances in how we design and activate the T cells. That led us to several landmark trials and ultimately the first CAR T-cell therapy approved by the U.S. Food and Drug Administration in 2017, which was tisagenlecleucel for pediatric and young adult patients that had…
Not rated yetEpisode 406: Drug Resistance Biomarkers and Their Impact on Cancer Treatment Choices
· 24 min
"Our goal of precision oncology has been to shift to tailored therapies that can help to improve treatment efficacy and ultimately improve patient outcomes. Resistance biomarker testing can help the care team to detect these genomic changes that the tumor may have acquired during therapy that makes the cells resistant to therapy. This information can be extremely helpful when we're talking about making choices about second-line or subsequent-line therapy," ONS member Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP®, advanced practice RN at the University of Texas MD Anderson Cancer Center in Houston, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about drug resistance biomarker testing. This podcast episode is sponsored by AstraZeneca. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes - This episode is not eligible for NCPD credit. - ONS Podcast™ episodes: - Episode 389: Biomarker Testing for Non-Small Cell Lung Cancer - Episode 373: Biomarker Testing in Prostate Cancer - Episode 169: How Biomarker Testing Drives the Use of Targeted Therapies - ONS Voice articles: - Help Your Patients Understand Biomarker Resistance Testing - Key Patient Education Points for Biomarker Resistance Testing - Quick Quiz: How Much Do You Know About Drug Resistance in Cancer? - Quick Quiz: How Much Do You Know About Somatic Biomarker Resistance Testing? - When Targeted Therapy Stops Working, What's Next? Discover How Biomarker Resistance Testing Opens New Doors - ONS Biomarker Database - Clinical Journal of Oncology Nursing article: Tumor-Agnostic Therapies Reshaping Cancer Care - ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses - ONS course: Genomic Foundations for Precision Oncology - ONS Genomics and Precision Oncology Learning Library - American Cancer Society Cancer Action Network: - Access to Biomarker Testing page - White paper: The Landscape of Biomarker Testing Coverage in the United States - Find out which states are currently discussing biomarker testing bills and how you can advocate for them through ONS. To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We know that biomarkers are playing an ever more important role in cancer care, and really, their use can range anywhere from helping us to confirm a given diagnosis, understand a patient's cancer susceptibility or risk, evaluate prognosis, as well as personalize treatment recommendations. … But in some cases, though, biomarkers can also help us to avoid therapies that are not likely to work. We also call these drug resistance biomarkers. These are those biomarkers that signify that a tumor is unlikely to respond to a given therapy." TS 1:50 "Resistance to cancer therapies is one of the most common issues that arises during cancer treatment. Because the populations of cancer cells within a tumor can be very diverse, when a given drug kills the cells that are sensitive to that therapy, it can also eventually leave behind resistant tumor cells, which can grow and multiply over time. So this can ultimately lead to a point where the treatment that was initially effective is no longer able to control the disease." TS 4:33 "While costs have come down, there can still be a cost associated with biomarker testing, and in some cases, this can be considered a barrier to care. What patients pay out of pocket can vary…
Not rated yetEpisode 405: Long-Term Multiple Myeloma Considerations for Oncology Nurses
· 34 min
"The disease is increasingly managed as a chronic condition rather than a diagnosis with an immediate terminal outcome. Particularly, with earlier and more effective and sustained treatment options, we can make this disease a very chronic, long-term, livable condition. I want to make sure that patients are aware that this is not a death sentence. This is something that patients can live with for the long term," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term multiple myeloma considerations for oncology nurses. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 6, 2027. Ann McNeill is on the speakers' bureau for Pfizer. This financial relationship has been mitigated. All other planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to multiple myeloma and treatment. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses - Episode 398: An Overview of Multiple Myeloma for Oncology Nurses - Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer - Episode 201: Which Survivorship Care Model Is Right for Your Patient? - ONS Voice articles: - Effective Care Transitions Are Essential for New Multiple Myeloma Treatments - Infection Prevention for Oncology Nurses - Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations - Nurse-Led Survivorship Programs - Sexual Considerations for Patients With Cancer - Oncology Nursing Forum articles: - A Qualitative Study of the Experiences of Living With Multiple Myeloma - Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study - ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) - ONS Huddle Cards: - Pain Management - Sexuality - Survivorship Care Plan - ONS Learning Libraries: - Hematology, Cellular Therapy, and Stem Cell Transplantation - Survivorship - ONS Symptom Intervention resources: - Chronic Pain - Fatigue - Peripheral Neuropathy - American Cancer Society: Living as a Multiple Myeloma Survivor - Blood Cancer United: Resources for Healthcare Professionals - International Myeloma Foundation: Resources and Support for the Myeloma Community - Multiple Myeloma Research Foundation: Empower Patients and the Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We do consider myeloma an incurable hematologic malignancy, even though we have had improvements in survival. But just like for any malignancy, our goal is to maximize survival. We want to eliminate as many myeloma cells as we possibly can. And subsequently, we want to improve the quality of life for these patients in the long term. So those are basically our treatment goals. That's what we think of when we're treating patients all throughout their treatment journey." TS 1:39 "It is very…
Not rated yetEpisode 404: Tailor Patient Treatment Education for Non-Oncology Indications
· 38 min
"We print education sheets that we have, and we say, 'Just ignore this part that says cancer. You're getting this med but for a different indication.' And then you have to really point out what our goals of care are. You're using the information that, as oncology nurses, we like and love, but we're having to cross it out and say, 'Just read this portion and just do this here.' And that can be challenging for the nurse and probably confusing for the patient," ONS member Brandy Thornberry, RN, OCN®, outpatient infusion and VAD supervisor at Logan Health in Kalispell, MT, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about education for patients receiving antineoplastic drugs for non-oncology indications. Taylor also spoke with ONS members Lizzy McMahon, BSN, RN, OCN®, and Jennifer Lynch, BSN, RN, TCTCN™, about general antineoplastic treatment education and tailoring education in the stem cell transplantation setting. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 27, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge of best practices for educating patients receiving antineoplastic therapies across oncology, non‑oncology, and stem cell transplant settings. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 259: Patient Education for Health Literacy and Limited English Proficiency - Episode 197: Patient Learning Needs and Educational Assessments - Episode 183: How Oncology Nurses Find and Use Credible Patient Education Resources - Episode 179: Learn How to Educate Patients During Immunotherapy - Episode 173: Oncology Nurses' Role in Stem Cell Transplants for Pediatric Sickle Cell Disease - ONS Voice articles: - Online Tool Helps You Apply Health Literacy Principles to Written Patient Education - Personalized Patient Education: Ensure Effective, Inclusive, and Equitable Patient Education With These Five Strategies - Policies and Procedures for Written Patient-Facing Cancer Education Materials - Oncology Nursing Forum article: An Integrative Review of Patient Education During Inpatient Hematopoietic Stem Cell Transplantation - ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library - Patient Education Sheets: Cancer Care, Explained (https://patienteducationsheets.com/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode McMahon: "A great question would be to ask the patient what they already know and what they're most concerned about or what their biggest questions are. This way, the nurse can tailor their education to make sure to focus on what the patient doesn't know yet and what they're most concerned about, while still touching on all the required education topics. … It's also important for nurses to continually be assessing the patient's readiness to learn throughout the education session, looking for nonverbal cues or verbal signs that the patient is overwhelmed or anxious because this is going to interfere with their ability to take in new information." TS 3:49 Thornberry: "A lot of the education sheets and the products for them explain it like, 'This…
Not rated yetEpisode 403: Pharmacology 101: Checkpoint Inhibitors
· 34 min
"Because the premise of immune checkpoint blockade centers around elevating the immune function, we should always take a great deal of caution around those patients who have high immune risks. Those include patients with autoimmune disorders. That's one of our biggest questions that we ask, usually every consult that we're seeing with solid tumor. 'Do you have any history of autoimmune disorders? Tell me a little bit more about it. Is it being treated? What are your symptoms like?' And then also patients who have undergone organ transplants. Now, interestingly, this does include stem cell transplants," Kelsey Finch, PharmD, BCOP, oncology pharmacist practitioner at Columbus Regional Health in Indiana, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about checkpoint inhibitors. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 20, 2027. Kelsey Finch has disclosed a speakers bureau relationship with AstraZeneca. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to checkpoint inhibitors in the treatment of cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Pharmacology 101 series - Episode 273: Updates in Chemotherapy and Immunotherapy - Episode 174: Administer Pembrolizumab Immunotherapy With Confidence - Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment - ONS Voice articles: - Here's Why Oncology Nurses Are Pivotal in Managing Immune-Related Adverse Events - Make Subcutaneous Administration More Comfortable for Your Patients - Nursing Considerations for ICI-Related Myocarditis - Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology - Postdischarge ICI Patient Education Eliminates Hospital Readmissions - Shorter Administration Times Still Require High-Acuity Care - ONS Voice oncology drug reference sheets: - Dostarlimab-Gxly - Nivolumab and Hyaluronidase-Nvhy - Nivolumab and Relatlimab-Rmbw - Pembrolizumab and Berahyaluronidase Alfa-Pmph - Retifanlimab-Dlwr - Toripalimab-Tpzi - ONS books: - Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) - Guide to Cancer Immunotherapy (second edition) - ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ - Clinical Journal of Oncology Nursing articles: - Immune Checkpoint Inhibitor–Related Myocarditis: Recognition, Surveillance, and Management - Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients - Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers - ONS Huddle Cards: - Checkpoint Inhibitors - Immunotherapy - ONS Learning Libraries: - Genomics and Precision Oncology Learning Library - Immuno-Oncology Learning Library - Drugs@FDA package inserts - National Comprehensive Cancer Network homepage (https://www.nccn.org/) - OncoLink: All About Immunotherapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Before immune checkpoint blockade, the two-year overall survival rate in metastatic melanoma was hovering around 10%. After these agents came to market, depending on the trial and the agents used, that number actually…
Not rated yet